Patents by Inventor Michael A. Palladino

Michael A. Palladino has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230210817
    Abstract: Disclosed herein are compositions and methods for treating neoplastic diseases. Included are compositions and methods that are effective against multiple myeloma cells resistant to conventional and bortezomib treatment. Furthermore, combination treatment with two different proteosome inhibitors is shown to be synergistic for treating multiple myeloma.
    Type: Application
    Filed: August 18, 2022
    Publication date: July 6, 2023
    Inventors: Kenneth C. ANDERSON, Dharminder CHAUHAN, Michael A. PALLADINO
  • Publication number: 20200206190
    Abstract: Disclosed herein are compositions and methods for treating neoplastic diseases. Included are compositions and methods that are effective against multiple myeloma cells resistant to conventional and bortezomib treatment. Furthermore, combination treatment with two different proteosome inhibitors is shown to be synergistic for treating multiple myeloma.
    Type: Application
    Filed: February 25, 2020
    Publication date: July 2, 2020
    Inventors: Kenneth C. ANDERSON, Dharminder CHAUHAN, Michael A. PALLADINO
  • Patent number: 10610517
    Abstract: Disclosed herein are compositions and methods for treating neoplastic diseases. Included are compositions and methods that are effective against multiple myeloma cells resistant to conventional and bortezomib treatment. Furthermore, combination treatment with two different proteosome inhibitors is shown to be synergistic for treating multiple myeloma.
    Type: Grant
    Filed: March 25, 2014
    Date of Patent: April 7, 2020
    Assignees: Celgene International II SÀRL, Dana-Farber Cancer Institute, Inc.
    Inventors: Kenneth C. Anderson, Dharminder Chauhan, Michael A. Palladino
  • Publication number: 20140349965
    Abstract: Disclosed herein are compositions and methods for treating neoplastic diseases. Included are compositions and methods that are effective against multiple myeloma cells resistant to conventional and bortezomib treatment. Furthermore, combination treatment with two different proteosome inhibitors is shown to be synergistic for treating multiple myeloma.
    Type: Application
    Filed: March 25, 2014
    Publication date: November 27, 2014
    Applicants: Dana-Farber Cancer Institute, Inc., Triphase Research and Development I Corp.
    Inventors: Kenneth C. Anderson, Dharminder Chauhan, Michael A. Palladino
  • Patent number: 8722724
    Abstract: Disclosed herein are compositions and methods for treating neoplastic diseases. Included are compositions and methods that are effective against multiple myeloma cells resistant to conventional and bortezomib treatment. Furthermore, combination treatment with two different proteosome inhibitors is shown to be synergistic for treating multiple myeloma.
    Type: Grant
    Filed: July 30, 2008
    Date of Patent: May 13, 2014
    Assignees: Triphase Research and Development I Corp., Dana-Farber Cancer Institute, Inc.
    Inventors: Kenneth C. Anderson, Dharminder Chauhan, Michael A. Palladino
  • Publication number: 20120238634
    Abstract: Described herein are chemical compounds and pharmaceutical compositions, including novel chemical compounds and pharmaceutical compositions thereof, useful in the treatment of various diseases and disease states. Also described are methods of synthesizing natural products and novel, structurally-related chemical compounds. More particularly, disclosed are new analogs of and processes for the preparation of compounds and pharmaceutical compositions thereof useful in the treatment of, for example, inflammation, cancer, multiple myeloma, cachexia, cardiovascular disease, anti-infectious, diabetes, otitis media, sinusitis and transplant rejection.
    Type: Application
    Filed: March 9, 2012
    Publication date: September 20, 2012
    Applicant: NEREUS PHARMACEUTICALS, INC.
    Inventors: Michael A. Palladino, Emmanuel A. Theodorakis, Venkat Rami Reddy Macherla, Ta-Hsiang Chao, Young-Ger Suh
  • Patent number: 8133915
    Abstract: Described herein are chemical compounds and pharmaceutical compositions, including novel chemical compounds and pharmaceutical compositions thereof, useful in the treatment of various diseases and disease states. Also described are methods of synthesizing natural products and novel, structurally-related chemical compounds. More particularly, disclosed are new analogs of and processes for the preparation of compounds and pharmaceutical compositions thereof useful in the treatment of, for example, inflammation, cancer, multiple myeloma, cachexia, cardiovascular disease, anti-infectious, diabetes, otitis media, sinusitis and transplant rejection.
    Type: Grant
    Filed: January 14, 2011
    Date of Patent: March 13, 2012
    Assignees: Nereus Pharmaceuticals, Inc., The Regents of the University of California
    Inventors: Michael A. Palladino, Emmanuel A. Theodorakis, Venkat Rami Reddy Macherla, Ta-Hsiang Chao, Young-Ger Suh
  • Patent number: 8129527
    Abstract: Compounds represented by the following structure (II) are disclosed: as are methods for making such compounds. Compositions and methods for treating various disease conditions including cancer and non-cancer diseases associated with vascular proliferation are also disclosed.
    Type: Grant
    Filed: November 2, 2007
    Date of Patent: March 6, 2012
    Assignee: Nereus Pharmacuticals, Inc.
    Inventors: Michael A. Palladino, George Kenneth Lloyd, Yoshio Hayashi
  • Publication number: 20110160309
    Abstract: Described herein are chemical compounds and pharmaceutical compositions, including novel chemical compounds and pharmaceutical compositions thereof, useful in the treatment of various diseases and disease states. Also described are methods of synthesizing natural products and novel, structurally-related chemical compounds. More particularly, disclosed are new analogs of and processes for the preparation of compounds and pharmaceutical compositions thereof useful in the treatment of, for example, inflammation, cancer, multiple myeloma, cachexia, cardiovascular disease, anti-infectious, diabetes, otitis media, sinusitis and transplant rejection.
    Type: Application
    Filed: January 14, 2011
    Publication date: June 30, 2011
    Applicant: Nereus Pharmaceuticals, Inc.
    Inventors: Michael A. Palladino, Emmanuel A. Theodorakis, Venkat Rami Reddy Macherla, Ta-Hsiang Chao, Young-Ger Suh
  • Patent number: 7956058
    Abstract: Compounds represented by the following structure (I) are disclosed: as are methods for making such compounds, wherein said methods comprise reacting a diacyldiketopiperazine with a first aldehyde to produce an intermediate compound; and reacting the intermediate compound with a second aldehyde to produce the class of compounds with the generic structure, where the first aldehyde and the second aldehydes are selected from the group consisting of an oxazolecarboxaldeyhyde, imidazolecarboxaldehyde, a benzaldehyde, imidazolecarboxaldehyde derivatives, and benzaldehyde derivatives, thereby forming the above compound wherein R1, R1?, R1?, R2, R3, R4, R5, and R6, X1 and X2, Y, Z, Z1, Z2, Z3, and Z4 may each be separately defined in a manner consistent with the accompanying description. Compositions and methods for treating cancer and fungal infection are also disclosed.
    Type: Grant
    Filed: June 7, 2006
    Date of Patent: June 7, 2011
    Assignee: Nereus Pharmaceuticals, Inc.
    Inventors: Yoshio Hayashi, Michael A. Palladino, Jr., Jennifer Grodberg
  • Patent number: 7935704
    Abstract: Compounds represented by the following structure (I) are disclosed: as are methods for making such compounds, wherein said methods comprise reacting a diacyldiketopiperazine with a first aldehyde to produce an intermediate compound; and reacting the intermediate compound with a second aldehyde to produce the class of compounds with the generic structure, where the first aldehyde and the second aldehydes are selected from the group consisting of an oxazolecarboxaldeyhyde, imidazolecarboxaldehyde, a benzaldehyde, imidazolecarboxaldehyde derivatives, and benzaldehyde derivatives, thereby forming the above compound wherein R1, R1?, R1?, R2, R3, R4, R5, and R6, X1 and X2, Y, Z, Z1, Z2, Z3, and Z4 may each be separately defined in a manner consistent with the accompanying description. Compositions and methods for treating vascular proliferation are also disclosed.
    Type: Grant
    Filed: February 4, 2005
    Date of Patent: May 3, 2011
    Assignee: Nereus Pharmaceuticals, Inc.
    Inventors: Michael A. Palladino, George Kenneth Lloyd, Yoshio Hayashi, Benjamin Nicholson
  • Patent number: 7893299
    Abstract: Described herein are chemical compounds and pharmaceutical compositions, including novel chemical compounds and pharmaceutical compositions thereof, useful in the treatment of various diseases and disease states. Also described are methods of synthesizing natural products and novel, structurally-related chemical compounds. More particularly, disclosed are new analogs of and processes for the preparation of compounds and pharmaceutical compositions thereof useful in the treatment of, for example, inflammation, cancer, multiple myeloma, cachexia, cardiovascular disease, anti-infectious, diabetes, otitis media, sinusitis and transplant rejection.
    Type: Grant
    Filed: July 14, 2006
    Date of Patent: February 22, 2011
    Assignees: Nereus Pharmaceuticals, Inc., The Regents of the University of California
    Inventors: Michael A. Palladino, Emmanuel A. Theodorakis, Venkat Rami Reddy Macherla, Ta-Hsiang Chao, Young Ger Suh
  • Patent number: 7674903
    Abstract: Compounds represented by the following structure (I) are disclosed: as are methods for making such compounds, wherein said methods comprise reacting a diacyldiketopiperazine with a first aldehyde to produce an intermediate compound; and reacting the intermediate compound with a second aldehyde to produce the class of compounds with the generic structure, where the first aldehyde and the second aldehydes are selected from the group consisting of an oxazolecarboxaldeyhyde, imidazolecarboxaldehyde, a benzaldehyde, imidazolecarboxaldehyde derivatives, and benzaldehyde derivatives, thereby forming the above compound wherein R1, R1?, R1?, R2, R3, R4, R5, and R6, X1 and X2, Y, Z, Z1, Z2, Z3, and Z4 may each be separately defined in a manner consistent with the accompanying description. Compositions and methods for treating cancer and fungal infection are also disclosed.
    Type: Grant
    Filed: June 7, 2006
    Date of Patent: March 9, 2010
    Assignee: Nereus Pharmaceuticals, Inc.
    Inventors: Yoshio Hayashi, Michael A. Palladino, Jr., Jennifer Grodberg
  • Publication number: 20090156469
    Abstract: Disclosed are methods of treating Waldenstrom's Macroglobulinemia comprising administering to the animal, a therapeutically effective amount of a heterocyclic compound of Formula I.
    Type: Application
    Filed: December 5, 2008
    Publication date: June 18, 2009
    Applicants: NEREUS PHARMACEUTICALS, INC., Dana-Farber Cancer Institute
    Inventors: Irene Ghobrial, Aldo Roccaro, Dharminder Chauhan, Kenneth Anderson, Michael A. Palladino
  • Publication number: 20090148445
    Abstract: The present application demonstrates that Salinosporamide A can be used to sensitize cancer cells to cancer therapy. Furthermore, the present application demonstrates that Salinosporamide A acts as a therapeutic agent to kill or inhibit cancer cells after sensitization of the cells by an antibody or other chemosensitizing reagents. The cancer cells can be either therapy-sensitive or therapy resistant. The present application further demonstrates that Salinosporamide A induces the expression of Raf kinase inhibitor protein (RKIP) and PTEN, tumor suppressor proteins, and inhibits the expression of YY1, a transcriptional regulator protein overexpressed in cancer cells and also inhibits the growth factor pleiotrophin (PTN).
    Type: Application
    Filed: November 6, 2006
    Publication date: June 11, 2009
    Applicants: The Regents of the University of California, Nereus Pharmaceuticals, Inc.
    Inventors: Benjamin Bonavida, Michael A. Palladino
  • Publication number: 20080221122
    Abstract: Compounds represented by the following structure (II) are disclosed: as are methods for making such compounds. Compositions and methods for treating various disease conditions including cancer and non-cancer diseases associated with vascular proliferation are also disclosed.
    Type: Application
    Filed: November 2, 2007
    Publication date: September 11, 2008
    Inventors: Michael A. Palladino, George Kenneth Lloyd, Yoshio Hayashi
  • Publication number: 20080064753
    Abstract: Described herein are chemical compounds and pharmaceutical compositions, including novel chemical compounds and pharmaceutical compositions thereof, useful in the treatment of various diseases and disease states. Also described are methods of synthesizing natural products and novel, structurally-related chemical compounds. More particularly, disclosed are new analogs of and processes for the preparation of compounds and pharmaceutical compositions thereof useful in the treatment of, for example, inflammation, cancer, multiple myeloma, cachexia, cardiovascular disease, anti-infectious, diabetes, otitis media, sinusitis and transplant rejection.
    Type: Application
    Filed: July 14, 2006
    Publication date: March 13, 2008
    Inventors: Michael A. Palladino, Emmanuel A. Theodorakis, Venkat Rami Reddy Macherla, Ta-Hsiang Chao, Young Ger Suh
  • Patent number: 7064201
    Abstract: Compounds represented by the following structure (I) are disclosed: as are methods for making such compounds, wherein said methods comprise reacting a diacyldiketopiperazine with a first aldehyde to produce an intermediate compound; and reacting the intermediate compound with a second aldehyde to produce the class of compounds with the generic structure, where the first aldehyde and the second aldehydes are selected from the group consisting of an oxazolecarboxaldeyhyde, imidazolecarboxaldehyde, a benzaldehyde, imidazolecarboxaldehyde derivatives, and benzaldehyde derivatives, thereby forming the above compound wherein R1, R1?, R1?, R2, R3, R4, R5, and R6, X1 and X2, Y, Z, Z1, Z2, Z3, and Z4 may each be separately defined in a manner consistent with the accompanying description. Compositions and methods for treating cancer and fungal infection are also disclosed.
    Type: Grant
    Filed: August 1, 2003
    Date of Patent: June 20, 2006
    Assignee: Nereus Pharmaceuticals, Inc.
    Inventors: Yoshio Hayashi, Michael A. Palladino, Jr., Jennifer Grodberg
  • Patent number: 7026322
    Abstract: Methods of using a compound, its pharmaceutically acceptable salts, and/or its pro-drug esters, in isolated form, to treat cancer, and methods for isolating, for formulating, and for administering the compound, salt, and/or pro-drug ester as an antitumor agent, wherein the compound, salt, or pro-drug ester has the following structure: wherein: R1, R2, R5, R7, and R8 are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C1-C24 alkyl, unsaturated C1-C24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, substituted nitro, phenyl, and substituted phenyl groups, R3, R4, and R6 are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C1-C12 alkyl, unsaturated C1-C12 alkenyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, and substituted
    Type: Grant
    Filed: August 1, 2003
    Date of Patent: April 11, 2006
    Assignee: Nereus Pharmaceuticals, Inc.
    Inventors: Yoshio Hayashi, Michael A. Palladino, Jr., Jennifer Grodberg
  • Publication number: 20040102454
    Abstract: Methods of using a compound, its pharmaceutically acceptable salts, and/or its pro-drug esters, in isolated form, to treat cancer, and methods for isolating, for formulating, and for administering the compound, salt, and/or pro-drug ester as an antitumor agent, wherein the compound, salt, or pro-drug ester has the following structure: 1
    Type: Application
    Filed: August 1, 2003
    Publication date: May 27, 2004
    Inventors: Yoshio Hayashi, Michael A. Palladino, Jennifer Grodberg